{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:09:40Z","timestamp":1782166180735,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93993-4","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:32:19Z","timestamp":1742387539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic potential of AAV2-shmTOR gene therapy in reducing retinal inflammation and preserving endothelial Integrity in age-related macular degeneration"],"prefix":"10.1038","volume":"15","author":[{"given":"Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Yun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Geun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sub","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Hyun Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Yoon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"93993_CR1","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/jamaophthalmol.2022.4401","volume":"140","author":"DB Rein","year":"2022","unstructured":"Rein, D. B. et al. Prevalence of Age-Related macular degeneration in the US in 2019. JAMA Ophthalmol. 140, 1202\u20131208 (2022).","journal-title":"JAMA Ophthalmol."},{"key":"93993_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong, W. L. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2, e106\u2013116 (2014).","journal-title":"Lancet Glob Health"},{"key":"93993_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gendis.2021.02.009","volume":"9","author":"Y Deng","year":"2022","unstructured":"Deng, Y. et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 9, 62\u201379 (2022).","journal-title":"Genes Dis."},{"key":"93993_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","volume":"75","author":"J Ambati","year":"2012","unstructured":"Ambati, J. & Fowler, B. J. Mechanisms of age-related macular degeneration. Neuron 75, 26\u201339 (2012).","journal-title":"Neuron"},{"key":"93993_CR5","doi-asserted-by":"publisher","first-page":"ORSF68","DOI":"10.1167\/iovs.13-12757","volume":"54","author":"C Bowes Rickman","year":"2013","unstructured":"Bowes Rickman, C., Farsiu, S., Toth, C. A. & Klingeborn, M. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. Invest. Ophthalmol. Vis. Sci. 54, ORSF68\u201380 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93993_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.17219\/acem\/27093","volume":"24","author":"HM Zajac-Pytrus","year":"2015","unstructured":"Zajac-Pytrus, H. M., Pilecka, A., Turno-Krecicka, A., Adamiec-Mroczek, J. & Misiuk-Hojlo, M. The dry form of Age-Related macular degeneration (AMD): the current concepts of pathogenesis and prospects for treatment. Adv. Clin. Exp. Med. 24, 1099\u20131104 (2015).","journal-title":"Adv. Clin. Exp. Med."},{"key":"93993_CR7","unstructured":"Hobbs, S. D., Tripathy, K. & Pierce, K. Wet Age-Related Macular Degeneration (AMD), in StatPearls (Treasure Island (FL) ineligible companies. Disclosure: Koushik Tripathy declares no relevant financial relationships with ineligible companies. Disclosure: Kristine Pierce declares no relevant financial relationships with ineligible companies.; (2024)."},{"key":"93993_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/138945011794182674","volume":"12","author":"C Campa","year":"2011","unstructured":"Campa, C. & Harding, S. P. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr. Drug Targets. 12, 173\u2013181 (2011).","journal-title":"Curr. Drug Targets"},{"key":"93993_CR9","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41598-020-59244-4","volume":"10","author":"M Zhang","year":"2020","unstructured":"Zhang, M. et al. Dysregulated metabolic pathways in age-related macular degeneration. Sci. Rep. 10, 2464 (2020).","journal-title":"Sci. Rep."},{"key":"93993_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41598-017-18487-4","volume":"8","author":"M Sasaki","year":"2018","unstructured":"Sasaki, M. et al. Gender-specific association of early age-related macular degeneration with systemic and genetic factors in a Japanese population. Sci. Rep. 8, 785 (2018).","journal-title":"Sci. Rep."},{"key":"93993_CR11","doi-asserted-by":"publisher","first-page":"16023","DOI":"10.1038\/sigtrans.2016.23","volume":"1","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Erratum: genetic and environmental factors strongly influence risk, severity and progression of age-related macular degeneration. Signal. Transduct. Target. Ther. 1, 16023 (2016).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"93993_CR12","doi-asserted-by":"publisher","first-page":"14451","DOI":"10.1038\/s41598-023-41610-7","volume":"13","author":"M Twarog","year":"2023","unstructured":"Twarog, M. et al. TNFalpha induced by DNA-sensing in macrophage compromises retinal pigment epithelial (RPE) barrier function. Sci. Rep. 13, 14451 (2023).","journal-title":"Sci. Rep."},{"key":"93993_CR13","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","volume":"73","author":"A Kauppinen","year":"2016","unstructured":"Kauppinen, A., Paterno, J. J., Blasiak, J., Salminen, A. & Kaarniranta, K. Inflammation and its role in age-related macular degeneration. Cell. Mol. Life Sci. 73, 1765\u20131786 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"93993_CR14","doi-asserted-by":"publisher","first-page":"1100254","DOI":"10.3389\/fnmol.2023.1100254","volume":"16","author":"X Fu","year":"2023","unstructured":"Fu, X. et al. Microglia: the breakthrough to treat neovascularization and repair blood-retinal barrier in retinopathy. Front. Mol. Neurosci. 16, 1100254 (2023).","journal-title":"Front. Mol. Neurosci."},{"key":"93993_CR15","doi-asserted-by":"crossref","unstructured":"Costa, C., Incio, J. & Soares, R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10, 149\u2013166 (2007).","DOI":"10.1007\/s10456-007-9074-0"},{"key":"93993_CR16","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.ophtha.2008.03.021","volume":"115","author":"R Klein","year":"2008","unstructured":"Klein, R. et al. Inflammation, complement factor h, and age-related macular degeneration: the Multi-ethnic study of atherosclerosis. Ophthalmology 115, 1742\u20131749 (2008).","journal-title":"Ophthalmology"},{"key":"93993_CR17","doi-asserted-by":"crossref","unstructured":"Velazquez-Soto, H. et al. Exogenous CFH modulates levels of Pro-Inflammatory mediators to prevent oxidative damage of retinal pigment epithelial cells with the At-Risk CFH Y402H variant. Antioxid. (Basel) 12 (2023).","DOI":"10.20944\/preprints202306.1148.v1"},{"key":"93993_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/0301-4738.36475","volume":"55","author":"RP Singh","year":"2007","unstructured":"Singh, R. P. & Kaiser, P. K. Role of Ranibizumab in management of macular degeneration. Indian J. Ophthalmol. 55, 421\u2013425 (2007).","journal-title":"Indian J. Ophthalmol."},{"key":"93993_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl. J. Med. 355, 1419\u20131431 (2006).","journal-title":"N Engl. J. Med."},{"key":"93993_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/2040622312446007","volume":"3","author":"M Ohr","year":"2012","unstructured":"Ohr, M. & Kaiser, P. K. Aflibercept in wet age-related macular degeneration: a perspective review. Ther. Adv. Chronic Dis. 3, 153\u2013161 (2012).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"93993_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/14712598.2015.1057565","volume":"15","author":"MH Yazdi","year":"2015","unstructured":"Yazdi, M. H., Faramarzi, M. A., Nikfar, S., Falavarjani, K. G. & Abdollahi, M. Ranibizumab and Aflibercept for the treatment of wet age-related macular degeneration. Expert Opin. Biol. Ther. 15, 1349\u20131358 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"93993_CR22","first-page":"361","volume":"19","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld, P. J., Rich, R. M., Lalwani, G. A. & Ranibizumab Phase III clinical trial results. Ophthalmol. Clin. North. Am. 19, 361\u2013372 (2006).","journal-title":"Ophthalmol. Clin. North. Am."},{"key":"93993_CR23","doi-asserted-by":"publisher","first-page":"943915","DOI":"10.3389\/fbioe.2022.943915","volume":"10","author":"D Song","year":"2022","unstructured":"Song, D., Liu, P., Shang, K. & Ma, Y. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front. Bioeng. Biotechnol. 10, 943915 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"93993_CR24","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/s41433-024-02998-2","volume":"38","author":"CJ Payne","year":"2024","unstructured":"Payne, C. J. et al. Real-world effects of anti-vascular endothelial growth factor injection frequency on visual outcomes in patients with diabetic macular oedema. Eye (Lond). 38, 1687\u20131693 (2024).","journal-title":"Eye (Lond)"},{"key":"93993_CR25","doi-asserted-by":"crossref","unstructured":"Spiewak, D., Drzyzga, L. & Dorecka, M. & Wygledowska-Promienska, D. Summary of the therapeutic options for patients with dry and neovascular AMD. J. Clin. Med. 13 (2024).","DOI":"10.3390\/jcm13144227"},{"key":"93993_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian, L. M., Liew, G., Teo, K. Y. C., Wong, T. Y. & Mitchell, P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J. Transl Med. 21, 133 (2023).","journal-title":"J. Transl Med."},{"key":"93993_CR27","doi-asserted-by":"publisher","first-page":"NP109","DOI":"10.1177\/11206721221143154","volume":"33","author":"A Saitta","year":"2023","unstructured":"Saitta, A., D\u2019Eliseo, L. A. & D\u2019Eliseo, D. Efficacy and safety of Brolucizumab for serous drusenoid pigment epithelium detachment non-responder to bevacizumab and Aflibercept. Eur. J. Ophthalmol. 33, NP109\u2013NP112 (2023).","journal-title":"Eur. J. Ophthalmol."},{"key":"93993_CR28","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2147\/OPTH.S171636","volume":"12","author":"P Pongsachareonnont","year":"2018","unstructured":"Pongsachareonnont, P., Mak, M. Y. K., Hurst, C. P. & Lam, W. C. Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to Ranibizumab treatment. Clin. Ophthalmol. 12, 1877\u20131885 (2018).","journal-title":"Clin. Ophthalmol."},{"key":"93993_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.17116\/oftalma2018134061116","volume":"134","author":"NA Ermakova","year":"2018","unstructured":"Ermakova, N. A. [The role of inflammation in Age-related macular degeneration]. Vestn Oftalmol. 134, 116\u2013123 (2018).","journal-title":"Vestn Oftalmol"},{"key":"93993_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/imm.13479","volume":"166","author":"W Fan","year":"2022","unstructured":"Fan, W. et al. Retinal microglia: functions and diseases. Immunology 166, 268\u2013286 (2022).","journal-title":"Immunology"},{"key":"93993_CR31","doi-asserted-by":"publisher","first-page":"1356957","DOI":"10.3389\/fopht.2024.1356957","volume":"4","author":"V Rajeswaren","year":"2024","unstructured":"Rajeswaren, V. et al. Elevated tumor necrosis factor alpha and vascular endothelial growth factor in intermediate age-related macular degeneration and geographic atrophy. Front. Ophthalmol. (Lausanne). 4, 1356957 (2024).","journal-title":"Front. Ophthalmol. (Lausanne)"},{"key":"93993_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12964-020-00692-w","volume":"19","author":"K Kunimura","year":"2021","unstructured":"Kunimura, K., Miki, S., Takashima, M. & Suzuki, J. I. S-1-propenylcysteine improves TNF-alpha-induced vascular endothelial barrier dysfunction by suppressing the GEF-H1\/RhoA\/Rac pathway. Cell. Commun. Signal. 19, 17 (2021).","journal-title":"Cell. Commun. Signal."},{"key":"93993_CR33","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3389\/fimmu.2019.01618","volume":"10","author":"Y Wooff","year":"2019","unstructured":"Wooff, Y., Man, S. M., Aggio-Bruce, R., Natoli, R. & Fernando, N. IL-1 family members mediate cell death, inflammation and angiogenesis in retinal degenerative diseases. Front. Immunol. 10, 1618 (2019).","journal-title":"Front. Immunol."},{"key":"93993_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/13816810.2021.1929337","volume":"42","author":"LS Makita","year":"2021","unstructured":"Makita, L. S. et al. Interleukin-1beta-31 (rs1143627) genetic variant and the risk of age-related macular degeneration in the Brazilian population. Ophthalmic Genet. 42, 533\u2013538 (2021).","journal-title":"Ophthalmic Genet."},{"key":"93993_CR35","doi-asserted-by":"publisher","first-page":"109556","DOI":"10.1016\/j.exer.2023.109556","volume":"233","author":"R Xiao","year":"2023","unstructured":"Xiao, R., Lei, C., Zhang, Y. & Zhang, M. Interleukin-6 in retinal diseases: from pathogenesis to therapy. Exp. Eye Res. 233, 109556 (2023).","journal-title":"Exp. Eye Res."},{"key":"93993_CR36","doi-asserted-by":"publisher","first-page":"18084","DOI":"10.1038\/s41598-021-97522-x","volume":"11","author":"S Droho","year":"2021","unstructured":"Droho, S., Cuda, C. M., Perlman, H. & Lavine, J. A. Macrophage-derived interleukin-6 is necessary and sufficient for choroidal angiogenesis. Sci. Rep. 11, 18084 (2021).","journal-title":"Sci. Rep."},{"key":"93993_CR37","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","volume":"97","author":"K Jomova","year":"2023","unstructured":"Jomova, K. et al. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. Arch. Toxicol. 97, 2499\u20132574 (2023).","journal-title":"Arch. Toxicol."},{"key":"93993_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2174\/1573403X14666180702152436","volume":"14","author":"AV Krylatov","year":"2018","unstructured":"Krylatov, A. V. et al. Reactive oxygen species as intracellular signaling molecules in the cardiovascular system. Curr. Cardiol. Rev. 14, 290\u2013300 (2018).","journal-title":"Curr. Cardiol. Rev."},{"key":"93993_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan, M. J. & Liu, Z. G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell. Res. 21, 103\u2013115 (2011).","journal-title":"Cell. Res."},{"key":"93993_CR40","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte, R. S., Chen, D. S. & Ferrara, N. VEGF in signaling and disease: beyond discovery and development. Cell 176, 1248\u20131264 (2019).","journal-title":"Cell"},{"key":"93993_CR41","doi-asserted-by":"crossref","unstructured":"Wang, Y., Fung, N. S. K., Lam, W. C. & Lo, A. C. Y. mTOR signalling pathway: A potential therapeutic target for ocular neurodegenerative diseases. Antioxid. (Basel) 11 (2022).","DOI":"10.3390\/antiox11071304"},{"key":"93993_CR42","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1167\/iovs.10-5280","volume":"51","author":"Y Chen","year":"2010","unstructured":"Chen, Y., Wang, J., Cai, J. & Sternberg, P. Altered mTOR signaling in senescent retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 51, 5314\u20135319 (2010).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93993_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.18632\/aging.100303","volume":"3","author":"C Zhao","year":"2011","unstructured":"Zhao, C. & Vollrath, D. mTOR pathway activation in age-related retinal disease. Aging (Albany NY). 3, 346\u2013347 (2011).","journal-title":"Aging (Albany NY)"},{"key":"93993_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar, V. et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal. Transduct. Target. Ther. 8, 375 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"93993_CR45","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.7150\/thno.26281","volume":"9","author":"J Huang","year":"2019","unstructured":"Huang, J. et al. Abnormal mTORC1 signaling leads to retinal pigment epithelium degeneration. Theranostics 9, 1170\u20131180 (2019).","journal-title":"Theranostics"},{"key":"93993_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s12035-012-8314-5","volume":"46","author":"E Russo","year":"2012","unstructured":"Russo, E., Citraro, R., Constanti, A. & De Sarro, G. The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis. Mol. Neurobiol. 46, 662\u2013681 (2012).","journal-title":"Mol. Neurobiol."},{"key":"93993_CR47","doi-asserted-by":"publisher","first-page":"9204","DOI":"10.1038\/s41598-018-27394-1","volume":"8","author":"R Fritsche-Guenther","year":"2018","unstructured":"Fritsche-Guenther, R. et al. Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations. Sci. Rep. 8, 9204 (2018).","journal-title":"Sci. Rep."},{"key":"93993_CR48","doi-asserted-by":"publisher","first-page":"18742","DOI":"10.1038\/s41598-019-55096-9","volume":"9","author":"SP Langdon","year":"2019","unstructured":"Langdon, S. P. et al. Evaluation of the dual mTOR\/PI3K inhibitors gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models. Sci. Rep. 9, 18742 (2019).","journal-title":"Sci. Rep."},{"key":"93993_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.omtm.2019.06.004","volume":"14","author":"SHS Lee","year":"2019","unstructured":"Lee, S. H. S. et al. Effects of stuffer DNA on the suppression of choroidal neovascularization by a rAAV expressing a mTOR-Inhibiting ShRNA. Mol. Ther. Methods Clin. Dev. 14, 171\u2013179 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"93993_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cpt.2022.09.001","volume":"1","author":"H Deng","year":"2023","unstructured":"Deng, H. et al. PI3K\/AKT\/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer. Cancer Pathog Ther. 1, 56\u201366 (2023).","journal-title":"Cancer Pathog Ther."},{"key":"93993_CR51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.15252\/embr.201439704","volume":"16","author":"P Rimmele","year":"2015","unstructured":"Rimmele, P. et al. Mitochondrial metabolism in hematopoietic stem cells requires functional FOXO3. EMBO Rep. 16, 1164\u20131176 (2015).","journal-title":"EMBO Rep."},{"key":"93993_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.64.7.39","volume":"64","author":"S Drag","year":"2023","unstructured":"Drag, S., Dotiwala, F. & Upadhyay, A. K. Gene therapy for retinal degenerative diseases: progress, challenges, and future directions. Invest. Ophthalmol. Vis. Sci. 64, 39 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93993_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1167\/iovs.61.2.45","volume":"61","author":"SHS Lee","year":"2020","unstructured":"Lee, S. H. S. et al. Inhibition of mTOR via an AAV-Delivered ShRNA tested in a rat OIR model as a potential antiangiogenic gene therapy. Invest. Ophthalmol. Vis. Sci. 61, 45 (2020).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93993_CR54","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.1167\/iovs.18-24926","volume":"59","author":"SHS Lee","year":"2018","unstructured":"Lee, S. H. S. et al. Intravitreal injection of AAV expressing soluble VEGF Receptor-1 variant induces Anti-VEGF activity and suppresses choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 59, 5398\u20135407 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93993_CR55","doi-asserted-by":"publisher","first-page":"e0269951","DOI":"10.1371\/journal.pone.0269951","volume":"17","author":"SHS Lee","year":"2022","unstructured":"Lee, S. H. S. et al. mTOR Inhibition as a novel gene therapeutic strategy for diabetic retinopathy. PLoS One. 17, e0269951 (2022).","journal-title":"PLoS One"},{"key":"93993_CR56","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1007\/s12035-021-02390-1","volume":"58","author":"T Xu","year":"2021","unstructured":"Xu, T. et al. The mTOR\/NF-kappaB pathway mediates neuroinflammation and synaptic plasticity in diabetic encephalopathy. Mol. Neurobiol. 58, 3848\u20133862 (2021).","journal-title":"Mol. Neurobiol."},{"key":"93993_CR57","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00204-019-02424-7","volume":"93","author":"A Park","year":"2019","unstructured":"Park, A. & Koh, H. C. NF-kappaB\/mTOR-mediated autophagy can regulate diquat-induced apoptosis. Arch. Toxicol. 93, 1239\u20131253 (2019).","journal-title":"Arch. Toxicol."},{"key":"93993_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbrc.2012.07.044","volume":"425","author":"CH Wang","year":"2012","unstructured":"Wang, C. H., Cao, G. F., Jiang, Q. & Yao, J. TNF-alpha promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt\/mTORC1 signaling. Biochem. Biophys. Res. Commun. 425, 33\u201338 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"93993_CR59","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/eye.2010.196","volume":"25","author":"Y Wang","year":"2011","unstructured":"Wang, Y., Wang, V. M. & Chan, C. C. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond). 25, 127\u2013139 (2011).","journal-title":"Eye (Lond)"},{"key":"93993_CR60","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/00001756-200405190-00015","volume":"15","author":"DR Seo","year":"2004","unstructured":"Seo, D. R., Kim, K. Y. & Lee, Y. B. Interleukin-10 expression in lipopolysaccharide-activated microglia is mediated by extracellular ATP in an autocrine fashion. Neuroreport 15, 1157\u20131161 (2004).","journal-title":"Neuroreport"},{"key":"93993_CR61","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1124\/mol.105.021436","volume":"70","author":"GJ Liu","year":"2006","unstructured":"Liu, G. J., Kalous, A., Werry, E. L. & Bennett, M. R. Purine release from spinal cord microglia after elevation of calcium by glutamate. Mol. Pharmacol. 70, 851\u2013859 (2006).","journal-title":"Mol. Pharmacol."},{"key":"93993_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","volume":"4","author":"J Karar","year":"2011","unstructured":"Karar, J. & Maity, A. PI3K\/AKT\/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4, 51 (2011).","journal-title":"Front. Mol. Neurosci."},{"key":"93993_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13041-023-01074-2","volume":"17","author":"V Xing","year":"2024","unstructured":"Xing, V., Biggar, K., Ferguson, S. S. G. & Hayley, S. In vitro modulation of mTOR and mGlur5 influence alpha-synuclein accumulation. Mol. Brain. 17, 9 (2024).","journal-title":"Mol. Brain"},{"key":"93993_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13036-021-00276-3","volume":"15","author":"BH Cha","year":"2021","unstructured":"Cha, B. H. et al. AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. J. Biol. Eng. 15, 24 (2021).","journal-title":"J. Biol. Eng."},{"key":"93993_CR65","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12886-022-02334-w","volume":"22","author":"B Asani","year":"2022","unstructured":"Asani, B. et al. Anti-angiogenic properties of Rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via Inhibition of the mTOR pathway. BMC Ophthalmol. 22, 138 (2022).","journal-title":"BMC Ophthalmol."},{"key":"93993_CR66","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1586\/ecp.10.6","volume":"3","author":"SJ McGimpsey","year":"2010","unstructured":"McGimpsey, S. J. & Chakravarthy, U. VEGF-targeted therapy and beyond: pharmacotherapy and emerging treatments in agerelated macular degeneration. Expert Rev. Clin. Pharmacol. 3, 243\u2013252 (2010).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"93993_CR67","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/aos.15783","volume":"102","author":"E Vinge","year":"2024","unstructured":"Vinge, E. & Bro, T. Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration. Acta Ophthalmol. 102, 478\u2013482 (2024).","journal-title":"Acta Ophthalmol."},{"key":"93993_CR68","doi-asserted-by":"publisher","first-page":"785292","DOI":"10.3389\/fped.2022.785292","volume":"10","author":"C Kondo","year":"2022","unstructured":"Kondo, C. et al. Characteristics of eyes developing retinal detachment after Anti-vascular endothelial growth factor therapy for retinopathy of prematurity. Front. Pediatr. 10, 785292 (2022).","journal-title":"Front. Pediatr."},{"key":"93993_CR69","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41433-021-01562-6","volume":"36","author":"JG Garweg","year":"2022","unstructured":"Garweg, J. G. et al. Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Eye (Lond). 36, 862\u2013868 (2022).","journal-title":"Eye (Lond)"},{"key":"93993_CR70","first-page":"0291","volume":"6","author":"X He","year":"2023","unstructured":"He, X. et al. AAV for gene therapy in ocular diseases: progress and prospects. Res. (Wash D C). 6, 0291 (2023).","journal-title":"Res. (Wash D C)"},{"key":"93993_CR71","doi-asserted-by":"crossref","unstructured":"Castro, B. F. M., Steel, J. C. & Layton, C. J. AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies. BioDrugs 38, 73\u201393 (2024).","DOI":"10.1007\/s40259-023-00629-y"},{"key":"93993_CR72","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"93993_CR73","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya, S. & Berns, K. I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 21, 583\u2013593 (2008).","journal-title":"Clin. Microbiol. Rev."},{"key":"93993_CR74","doi-asserted-by":"publisher","first-page":"16586","DOI":"10.1073\/pnas.1314575110","volume":"110","author":"Y Du","year":"2013","unstructured":"Du, Y., Veenstra, A., Palczewski, K. & Kern, T. S. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc. Natl. Acad. Sci. U S A. 110, 16586\u201316591 (2013).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"93993_CR75","doi-asserted-by":"publisher","first-page":"1059947","DOI":"10.3389\/fimmu.2022.1059947","volume":"13","author":"L Zhao","year":"2022","unstructured":"Zhao, L., Hou, C. & Yan, N. Neuroinflammation in retinitis pigmentosa: therapies targeting the innate immune system. Front. Immunol. 13, 1059947 (2022).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93993-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T19:32:52Z","timestamp":1742412772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93993-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93993-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5150466\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No consent to participate was required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"9517"}}